Printer Friendly

CYTOGEN ANNOUNCES PROGRESS ON SAMARIUM EDTMP, FINANCIAL OUTLOOK

 PRINCETON, N.J., Nov. 3 /PRNewswire/ -- CYTOGEN Corporation (NASDAQ: CYTO) presented an update on its Revised Strategic Plan today at the 4th Annual Healthcare Conference in New York City.
 The presentation by President Dr. Thomas J. McKearn and Vice President and Chief Financial Officer T. Jerome Madison provided an update on both the product development efforts for CYT-424 (Samarium EDTMP), a therapy agent for the alleviation of pain associated with bone metastases, and on CYTOGEN's financial outlook.
 CYTOGEN Corporation's new priorities set out under the Revised Strategic Plan announced on Sept. 17, 1993, called for a high prioritization of clinical development efforts for CYT-424. At today's conference, Dr. McKearn stated that the company continues to anticipate the filing of a New Drug Application for this product to the FDA in 1994. Phase III trials of CYT-424, currently underway in the U.S. and Europe, continue to progress satisfactorily.
 CYTOGEN Corporation's financial outlook was also addressed in today's presentation. T. Jerome Madison, Vice President and CFO explained, "The combined effects of the CYTOGEN's Revised Strategic Plan will lower 1994 operating expenses by approximately $10 million from previously budgeted levels. We estimate approximately $26 million in operating expenses for 1994." Madison cited the re-prioritized product development programs, a 30 percent decrease in work force, the elimination of 30 additional positions which had been previously budgeted, and other cost-saving measures as contributing factors to the $10 million reduction.
 CYTOGEN is a biopharmaceutical company engaged in the marketing and development of products for the targeted delivery of diagnostic and therapeutic substances directly to sites of disease. CYTOGEN uses its patented and proprietary "linker" technology primarily to develop specific cancer diagnostic imaging and cancer therapeutic products.
 /delval/
 -0- 11/3/93
 /CONTACT: Mary Beals, director, Corporate Communications, of CYTOGEN, 609-987-8221/
 (CYTO)


CO: Cytogen Corporation ST: New Jersey IN: MTC SU: ERP

MK -- PH018 -- 0128 11/03/93 11:59 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 3, 1993
Words:315
Previous Article:THE ROUSE COMPANY ANNOUNCES THIRD QUARTER RESULTS
Next Article:PHELPS DODGE CORPORATION DECLARES FOURTH QUARTER DIVIDEND
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters